Hot Features
Premium
Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 4,903 |
|
|||||
| News | - | ||||||
| Day High | 3.30 | Low High |
|||||
| Day Low | 2.83 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Anebulo Pharmaceuticals Inc | ANEB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.1499 | -5.00% | 2.85 | 15:00:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.91 | 2.83 | 3.30 | 2.85 | 2.9999 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 100 | 4,903 | US$ 3.10 | US$ 15,209 | - | 1.62 - 4.05 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 10 | US$ 2.75 | USD |
Anebulo Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 73.91M | 25.93M | - | 0 | -11.73M | -0.45 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Anebulo Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/13/2024 | 15:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2/13/2024 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/13/2024 | 15:05 | Business Wire | Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year.. |
| 11/21/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2023 | 15:05 | Business Wire | Anebulo Pharmaceuticals Reports First Quarter Fiscal Year.. |
| 10/30/2023 | 08:31 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders |
| 10/30/2023 | 08:22 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 10/19/2023 | 16:18 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 10/06/2023 | 15:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/06/2023 | 15:06 | Business Wire | Anebulo Pharmaceuticals Announces New CEO |
| 10/02/2023 | 16:01 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
| 9/22/2023 | 15:05 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANEB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.77 | 3.30 | 2.612 | 2.92 | 3,010 | 0.08 | 2.89% |
| 1 Month | 2.43 | 3.30 | 2.40 | 2.80 | 5,541 | 0.42 | 17.28% |
| 3 Months | 2.42 | 3.30 | 2.40 | 2.70 | 5,940 | 0.43 | 17.77% |
| 6 Months | 2.53 | 3.30 | 1.87 | 2.38 | 10,893 | 0.32 | 12.65% |
| 1 Year | 2.88 | 4.05 | 1.62 | 2.49 | 9,498 | -0.03 | -1.04% |
| 3 Years | 7.38 | 9.33 | 1.62 | 4.62 | 10,543 | -4.53 | -61.38% |
| 5 Years | 7.38 | 9.33 | 1.62 | 4.62 | 10,543 | -4.53 | -61.38% |
Anebulo Pharmaceuticals Description
| Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. |
